A novel cabozantinib formulation with improved safety and bioavailability: preclinical validation in rats
Cancer Chemotherapy and Pharmacology · 14.03.2026 · 96 (1)
DOI: 10.1007/s00280-026-04875-z ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 14.03.2026. Verfasst von Shangwei Qin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hangzhou Handa Pharmaceutical Technology Co., Ltd., Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Pyridines, Anilides, Protein Kinase Inhibitors. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Handa Pharmaceuticals, Inc..
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hangzhou Handa Pharmaceutical Technology Co., Ltd., Hangzhou, Zhejiang, China.
- Handa Pharmaceuticals, Inc., Tainan, Taiwan.
- Handa Pharmaceuticals, Inc., California, USA. george.kraft@handapharma.com.
- School of Biomedicine, The University of Adelaide, Adelaide, Australia.
Förderung
- Handa Pharmaceuticals, Inc.
Zitieren
APA
Qin, S., Zhang, Y., Duan, J., Kraft, G., & Bowen, J. (2026). A novel cabozantinib formulation with improved safety and bioavailability: preclinical validation in rats. Cancer Chemotherapy and Pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04875-z
Vancouver
Qin S, Zhang Y, Duan J, Kraft G, Bowen J. A novel cabozantinib formulation with improved safety and bioavailability: preclinical validation in rats. Cancer Chemotherapy and Pharmacology. 2026;96(1). doi:10.1007/s00280-026-04875-z
BibTeX
@article{Qin2026,
author = {Qin, Shangwei and Zhang, Yu and Duan, John and Kraft, George and Bowen, Joanne},
title = {A novel cabozantinib formulation with improved safety and bioavailability: preclinical validation in rats},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2026},
volume = {96},
number = {1},
doi = {10.1007/s00280-026-04875-z}
}
EUVIMED